Paramount Skydance to Acquire Warner Bros Discovery in $110 Billion Media Mega-Deal 
Trump Media Weighs Truth Social Spin-Off Amid $6B Fusion Energy Pivot 
Trump Warns Iran as Gulf Conflict Disrupts Oil Markets and Global Trade 
Bank of Japan Signals Further Interest Rate Hikes as Inflation Trends Toward 2% Target 
USITC to Review Impact of Revoking China’s PNTR Status, Potentially Raising Tariffs on Chinese Imports 
Boeing Secures $166.8 Million U.S. Navy Contract for P-8A Engineering and Software Support 
Samsung Electronics Stock Poised for $1 Trillion Valuation Amid AI and Memory Boom 
Wall Street Futures Tumble as U.S.-Iran Conflict Escalates and Oil Prices Surge 
Anthropic Refuses Pentagon Request to Remove AI Safeguards Amid Defense Contract Dispute 
U.S. Stock Futures Fall as Nvidia Drops Despite Strong Earnings; Netflix Jumps 9% 
MOEX Russia Index Hits 3-Month High as Energy Stocks Lead Gains 
Oil Prices Surge 13% as U.S.-Israel Strikes on Iran Spark Supply Fears 
Global Markets Reel as Euro Falls, Swiss Franc Surges and Oil Prices Spike After U.S.-Israel Strike on Iran 
Gold Prices Steady in Asia, Set for Strong February Gains on Safe-Haven Demand 
Stock Market Movers: Dell, Block, Duolingo, Zscaler, CoreWeave, Autodesk, Rocket, MARA 
Australian Dollar Rallies on Hawkish RBA Outlook; Yen Slips as BOJ Faces Political Pressure 
Hyundai Motor Group to Invest $6.26 Billion in AI Data Center, Robotics and Renewable Energy Projects in South Korea 
Lotte Group is set to acquire a bioindustry CMO plant located in the United States. The move has been announced on Thursday, May 5, and this also signals the company’s entrance into the bio business.
Currently, the acquisition process for the contract manufacturing organization (CMO) facility is still ongoing. Investment banking industry insiders said that Lotte Group has taken this step to buy the CMO plant after it stated that the bioindustry will be its new growth engine.
According to The Korea Times, CMOs are firms that specialize in the production of biopharmaceuticals that were developed by other companies. Lotte Group’s new CMO business will be headed by Lee Won Jik, a former executive at Samsung Biologics that the company recently hired. He has been tasked to develop and grow this business unit that the Lotte Group set up.
Lee will also be leading the acquisition efforts of the CMO as per the report. It was only last month when the South Korean multinational conglomerate declared during its general shareholders' meeting that its next growth engine for the future will be the bioindustry. Lotte Holdings will be investing directly in this business and will provide support to help it grow and succeed.
Meanwhile, as part of its entrance into the CMO business, Lotte Group applied for a trademark for its new biz. The company registered “Lotte Biologics” with the Korean Intellectual Property Office (KIPO) to officially launch its bio venture.
It was added that under the new Lotte Biologics banner, Lotte will also be participating in the largest bioindustry expo in the world called the Bio International Convention (Bio USA) which is set to take place next month in San Diego, California.
KIPO revealed that Lotte Holdings applied for the patent last week and aside from the name, it also trademarked some business areas such as customized manufacturing of biopharmaceuticals and drug processing and medical diagnostic devices for virus testing, The Korea Herald reported.
“Registering the trademark of Lotte Biologics was a part of preparations for the group’s bio business,” an official of Lotte Holdings stated. “We are reviewing various ways to enter the bio industry, but nothing has been confirmed at the moment.”
